Plexium

Plexium is a leading biotechnology company dedicated to the development of transformative precision medicines for patients in need. They specialize in targeted protein degradation (TPD), a novel approach to drug discovery that utilizes small molecules to selectively degrade disease-causing proteins. Their proprietary platform utilizes cutting-edge technologies, including ultra-high throughput cell-based screening, to identify and develop novel monovalent degrader drug candidates. Their diverse pipeline includes programs focused on neurological conditions, oncology, and other diseases with significant unmet medical needs.

Plexium's commitment to innovation is evident in their highly collaborative and entrepreneurial team, which comprises world-class experts in medicinal chemistry, biology, and technology. They have garnered significant investor support and have established partnerships with major pharmaceutical companies, including AbbVie, to accelerate the development and commercialization of their groundbreaking therapeutics. Plexium's vision is to revolutionize the treatment of diseases by harnessing the power of targeted protein degradation.

Plexium is a next-generation targeted protein degradation (TPD) company dedicated to rationally designing and discovering innovative monovalent protein degrader therapeutics. They leverage a proprietary, ultra-high throughput cell-based screening (uHTS) platform to develop a diverse portfolio of targeted therapies that address significant unmet medical needs, particularly in the areas of oncology and neurology. Their mission is to deliver transformative precision medicines to patients in need, pushing the boundaries of TPD and creating limitless possibilities for treating complex diseases.

Plexium fosters a collaborative and entrepreneurial culture, driven by a shared commitment to deliver life-changing medicines. The company encourages innovation and teamwork among its world-class team, creating an environment where employees are empowered to push boundaries and contribute to the development of transformative precision medicines.